How to Help Your Patients Save Money on Keppra: A Provider's Guide to Savings Programs

Medication cost is a significant driver of non-adherence in epilepsy — and for a medication like levetiracetam where missed doses carry real seizure risk, this is a patient safety issue, not just a billing problem. Fortunately, levetiracetam is one of the more affordable anti-seizure medications available, and most patients have meaningful options to reduce their out-of-pocket costs. This guide helps providers understand the current cost landscape and gives them practical tools to share with patients.

The Current Cost Landscape for Levetiracetam (2026)

Understanding the pricing environment helps providers counsel patients and write cost-effective prescriptions:

Generic levetiracetam IR (500 mg, 60 tablets): Average retail $65–$153; as low as $6–$7 with GoodRx or SingleCare coupons

Generic levetiracetam ER (30-day supply): ~$114 retail; as low as $15–$22 with coupons

Brand Keppra (60 x 500 mg tablets): ~$810 without insurance — not covered by Medicare; limited coverage by most commercial plans

Insurance copay (generic, Tier 1–2): Typically $0–$30 for a 30-day supply on most commercial and Part D plans

Strategy 1: Prescribe Generic Levetiracetam (Not Brand Keppra)

The single most impactful prescribing decision is writing for generic levetiracetam rather than brand Keppra. Generic levetiracetam has been available since 2008 and is bioequivalent to brand Keppra. The cost difference is dramatic: $6–$65 for generic vs. $800+ for brand.

Some epilepsy specialists maintain a clinical preference for manufacturer consistency — recommending patients stay on the same generic manufacturer rather than switching repeatedly. This is a reasonable and defensible approach. However, the switch from brand to generic is generally considered safe, and studies examining Keppra-to-generic bioequivalence (including one published in Clinical Neuropharmacology, 2017) have found comparable clinical outcomes.

Strategy 2: Write for a 90-Day Supply When Appropriate

For patients on stable levetiracetam regimens, writing for a 90-day supply offers several advantages:

Most insurance plans offer lower per-unit pricing for 90-day fills vs. three 30-day fills

Mail-order pharmacies (preferred for 90-day fills by many plans) rarely run out of levetiracetam, reducing stock gap risk

Fewer pharmacy visits means fewer opportunities to miss a pickup and run out unexpectedly

Note: most insurance plans require a new prescription specifically written for a 90-day supply — a 30-day prescription cannot be converted at the pharmacy counter. Also, mail-order enrollment may need to be set up by the patient with their insurance plan.

Strategy 3: Counsel Patients on GoodRx and Prescription Discount Programs

For patients who are uninsured, underinsured, or whose insurance copay exceeds the coupon price, prescription discount programs like GoodRx and SingleCare can dramatically reduce cost. Generic levetiracetam can be obtained for as little as $6–$7 per 30-day supply through these programs — a 90%+ reduction from retail.

Key counseling points for patients:

Coupons cannot be combined with insurance — use whichever gives the lower out-of-pocket cost

Coupon prices vary by pharmacy — it's worth comparing 2–3 nearby pharmacies using the GoodRx or SingleCare app

These programs are not insurance but can be used repeatedly and are available to patients at any income level

Strategy 4: UCB Patient Assistance for Brand Keppra and Spritam

For patients who require brand Keppra or Spritam (the 3D-printed rapid-dissolve formulation) and cannot afford it, UCB Pharmaceuticals offers patient assistance programs. These programs are typically available for patients who are:

Uninsured or underinsured

At or below income eligibility thresholds set by UCB

Unable to access the medication through other programs

Contact UCB at 1-800-UCB-5555 or direct patients to NeedyMeds.org and RxAssist.org for a comprehensive search of all available programs.

Strategy 5: Prior Authorization Navigation for Extended-Release Formulations

Generic immediate-release levetiracetam rarely requires prior authorization. Extended-release formulations (generic Keppra XR) are more commonly subject to coverage restrictions. If a patient requires the XR formulation (e.g., for once-daily dosing adherence, or because IR is not tolerated), be prepared to document medical necessity in a PA request. Common justifications include:

Documented non-adherence with twice-daily IR dosing

Improved seizure control or tolerability with XR vs. IR (document seizure log)

Reduced peak-dose side effects with XR formulation

Strategy 6: Help Patients Find Levetiracetam in Stock to Avoid Costly Gaps

Cost savings mean nothing if the patient can't find their medication. Stock gaps add a hidden cost burden — time off work, transportation to multiple pharmacies, or emergency room visits if seizures occur due to missed doses. Consider providing patients with information about medfinder, a service that calls pharmacies near the patient to check current levetiracetam availability, then texts them results. This reduces the patient's search burden and decreases the risk of medication gaps.

Summary: Provider Checklist for Keppra Cost Reduction

Write for generic levetiracetam unless there is a medical reason for brand

Write for 90-day supply for stable patients — specify this on the prescription

Counsel patients on GoodRx/SingleCare coupons as an alternative to insurance for uninsured patients or high-copay plans

For uninsured patients needing brand: refer to UCB patient assistance at 1-800-UCB-5555

For XR formulations requiring PA: document medical necessity proactively

Direct patients to medfinder.com to locate stock if availability becomes an issue

For the clinical perspective on supply issues, see our provider guide: Keppra Shortage: What Providers Need to Know in 2026.